Ichor Biologics

What Ichor Biologics does

Ichor Biologics is a New York City-based, pre-clinical biotechnology company founded in 2014 that develops antibody-based therapeutics for infectious diseases. The company's core offering is a high-throughput platform for isolating and characterizing naturally-occurring human monoclonal antibodies by exploiting immunological signatures of natural human resistance to pathogens — leveraging the observation that a small subset of exposed individuals naturally control or clear infections. The platform rests on three technology pillars: novel assays that measure pathogen-specific immune responses in patients years after recovery, an efficient proprietary methodology for producing pathogen antigens, and machine learning software for identifying antibody binding sites and engineering improved antibody variants. Its lead program targets Andes hantavirus and consists of two antibody candidates that demonstrated 100% protection in lethal-challenge animal studies, published in Science Translational Medicine in November 2018, and have received FDA Orphan Drug Status.

Ichor operates with 1–10 employees from a single NYC headquarters and has no commercial products, revenue, or disclosed institutional equity capital. The stated business model is to generate antibody-related intellectual property through preclinical validation and then license or co-develop these assets with industry partners that provide clinical trial pipeline access — a licensing/royalty model contingent on closing a future partnership. To date, the company has funded operations through approximately $850,000 in non-dilutive grants from the NIH and Chile's FONDEF, and maintains international research collaborations with the NIH, University of Concepción in Chile, the Robert Koch Institute, and Rocky Mountain Laboratories.

Name

Ichor Biologics

Legal name

Ichor Biologics

Website

https://ichorbiologics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Ichor Biologics is a New York City-based pre-clinical biotechnology company developing antibody-based therapeutics for infectious diseases, with its lead program targeting hantavirus infections using a proprietary platform for isolating naturally-occurring human monoclonal antibodies.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Strategic Partnerships and Licensing: Pre-clinical stage company that aims to leverage its antibody development platform technology to produce antibody-related intellectual property through preclinical validation stage, then establish strategic partnerships or licensing deals with industry partners for clinical trial pipeline access.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ichor Biologics develops a high-throughput platform for the isolation and characterization of naturally-occurring human monoclonal antibodies against infectious diseases, with its lead programs targeting deadly hantavirus infections. The company is pre-clinical and aims to leverage its antibody-related intellectual property through strategic partnerships or licensing deals with industry partners to access clinical trial pipelines.

Product overview

Ichor Biologics offers a unified antibody-based therapeutics platform focused on infectious diseases. The core platform enables high-throughput isolation of naturally-occurring human monoclonal antibodies through three technological pillars: immune response identification, antigen production, and proprietary machine learning for antibody optimization. The company's two lead antibody drug candidates target deadly hantavirus infections and demonstrated 100% protection in animal studies, achieving FDA orphan drug status. The platform is designed to accelerate therapeutic development by rapidly producing antibody-based therapeutics with high safety and clinical efficacy profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody-Based Therapeutics Platform

Quantifiable outcome

• 100% animal survival against lethal hantavirus infections with two lead antibody-based drugs
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and major.

• University of Concepción (Chile)coreStrategic or Co-development PartnerCollaboration with researchers from NIH and Universidad de Concepción in Chile to develop antibody-based drugs against hantavirus infections. Joint research published in Science Translational Medicine demonstrated 100% protection in animals against lethal hantavirus infections.
• Rocky Mountain LaboratoriesmajorStrategic or Co-development PartnerInternational research partner collaborating on hantavirus antibody development alongside Ichor Biologics, University of Concepción, Robert Koch Institute, and NIH.
• Robert Koch InstitutemajorStrategic or Co-development PartnerInternational research partner collaborating on hantavirus vaccine development as part of the Chilean research team alongside Ichor Biologics and NIH.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Vir Biotechnology: Clinical-stage immunology company developing antibody-based therapeutics for serious infectious diseases, including coronaviruses, influenza, and hepatitis B. Closely comparable to Ichor in modality (human monoclonal antibodies), target space (infectious diseases), and partnership-driven business model.
• AbCellera Biologics: AI/ML-enabled antibody discovery platform company partnering with pharma to rapidly isolate fully human monoclonal antibodies from natural immune repertoires. Directly comparable to Ichor on platform technology (high-throughput antibody isolation), use of ML, and partnership/licensing revenue model.

Emerging players

• Mapp Biopharmaceutical: Small, privately-held biotech focused on monoclonal antibodies for emerging infectious diseases and biodefense (notably ZMapp for Ebola). Comparable in scale and stage to Ichor with a similar focus on pathogen-specific human mAbs and government/biodefense funding.
• Adagene: Clinical-stage biotech using AI-powered antibody discovery and engineering to generate novel therapeutic antibodies, primarily in oncology but with platform overlap to Ichor's AI/ML-enabled discovery approach.
• Arcturus Therapeutics: Clinical-stage mRNA and RNAi therapeutics company with significant infectious-disease programs (including COVID-19 vaccines). Different modality but comparable pre-clinical-to-clinical infectious-disease trajectory and partnership-heavy commercialization model.

Broad incumbents

• Regeneron Pharmaceuticals: Large-cap biopharma with a flagship VelocImmune human antibody platform that produced REGN-COV2 (casirivimab/imdevimab) for COVID-19. Operates broadly across therapeutic areas but is the canonical benchmark for high-throughput human monoclonal antibody discovery at scale.
• AstraZeneca (including Alexion): Developed and commercialized antibody combinations (e.g., Evusheld, sipavibart) for COVID-19 prevention and other infectious diseases. A natural potential licensee for early-stage infectious-disease antibody assets like Ichor's.
• Eli Lilly (Lilly infectious disease antibodies): Developed bamlanivimab, etesevimab, and bebtelovimab as monoclonal antibodies against SARS-CoV-2. Represents the established large-pharma archetype for infectious-disease antibody development and a likely licensing partner.
• Emergent BioSolutions: Specialty biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases and biodefense threats (e.g., anthrax, smallpox). Comparable end-customer set (government health agencies) and infectious-disease therapeutic focus.

Others

• Celdara Medical: Early-stage biotech incubator/venture builder that has worked with academic and small biotech founders (including recognizing Ichor at the 2016 Celdara pitch competition). Acts as a development partner and investor in similar early-stage antibody and cell-therapy companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ichor-biologics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ichor Biologics